Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC

被引：0
|
作者：
Xu, R. [1 ]
Li, Y. [1 ]
Luo, H. [1 ]
Wang, W. [2 ]
Wang, Z. [1 ]
Yuan, X. [3 ]
Ma, D. [4 ]
Wang, F. H. [1 ]
Zhang, D. [1 ]
Lin, D. R. [5 ,6 ]
Jia, J.
Hu, X. H. [7 ]
Peng, J. W. [8 ]
Lin, Y. C. [9 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] Foshan 1 Peoples Hosp, Med Oncol, Foshan, Peoples R China
[3] Huizhou Cent Hosp, Med Oncol, Huizhou, Peoples R China
[4] Guangdong Gen Hosp, Med Oncol, Huizhou, Peoples R China
[5] Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China
[6] Dongguan Peoples Hosp, Med Oncol, Dongguan, Peoples R China
[7] Guangxi Med Univ, Canc Hosp, Med Oncol, Nanning, Peoples R China
[8] Zhongshan Peoples Hosp, Med Oncol, Zhongshan, Peoples R China
[9] Shantou Univ, Canc Hosp, Med Oncol, Shantou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142O
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [31] A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer
    Bendell, Johanna C.
    Joseph, Mathew
    Barnes, Kirk
    Mainwaring, Mark
    Shipley, Dianna
    Reddy, Chandra
    Blakely, Laura
    Blachly, Ronald
    Lane, Cassie M.
    Earwood, Chris
    Kuzur, Michel
    CANCER INVESTIGATION, 2017, 35 (06) : 386 - 392
  • [32] First-line single-agent cetuximab in patients with advanced colorectal cancer
    Pessino, A.
    Artale, S.
    Sciallero, S.
    Guglielmi, A.
    Fornarini, G.
    Andreotti, I. C.
    Mammoliti, S.
    Comandini, D.
    Caprioni, F.
    Bennicelli, E.
    Andretta, V.
    Siena, S.
    Sobrero, A.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 711 - 716
  • [33] First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.
    Pietrantonio, Filippo
    Morano, Federica
    Corallo, Salvatore
    Lonardi, Sara
    Cremolini, Chiara
    Rimassa, Lorenza
    Sartore-Bianchi, Andrea
    Tampellini, Marco
    Bustreo, Sara
    Clavarezza, Matteo
    Murialdo, Roberto
    Zaniboni, Alberto
    Adamo, Vincenzo
    Tomasello, Gianluca
    Giordano, Monica
    Petrelli, Fausto
    Longarini, Raffaella
    Zagonel, Vittorina
    Di Bartolomeo, Maria
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Cost comparison of XELOX vs. FOLFOX4 ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (MCRC):: US findings
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V
    Ervin, R.
    Stella, P.
    Saltz, L.
    ANNALS OF ONCOLOGY, 2007, 18 : VII74 - VII74
  • [35] Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
    Geng, Rui
    Wang, Gang
    Qiu, Lei
    Liu, Bing
    Yang, Fan
    Zhang, Jingyu
    Miao, Yongchang
    MEDICINE, 2020, 99 (51) : E23719
  • [36] Analysis of potential predictive factors of clinical benefit in patients (pts) with metastatic colorectal cancer (MCRC) treated with single-agent cetuximab as first-line treatment
    Gravalos, C.
    Sastre, J.
    Aranda, E.
    Massuti, B.
    Vega-Villegas, M. E.
    Gomez, A.
    Varella-Garcia, M.
    Jimeno, A.
    Diaz-Rubio, E.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Maintenance therapy or aEurotreatment holiday" after first-line therapy
    Serke, M.
    ONKOLOGE, 2011, 17 (08): : 709 - 714
  • [38] First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study
    Pietrantonio, Filippo
    Caporale, Marta
    Berenato, Rosa
    Lonardi, Sara
    Murialdo, Roberto
    Paterno, Emanuela
    Tampellini, Marco
    Bertolini, Alessandro Stefano
    Rimassa, Lorenza
    Cremolini, Chiara
    Giommoni, Elisa
    Tomasello, Gianluca
    Longarini, Raffaella
    Petrelli, Fausto
    Zaniboni, Alberto
    Cortesi, Enrico
    Bianchi, Andrea Sartore
    Bossi, Ilaria
    Di Bartolomeo, Maria
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Pessino, A.
    Artale, S.
    Guglielmi, A.
    Sciallero, S.
    Fornarini, G.
    Andreotti, I. C.
    Mammoliti, S.
    Marrapese, G.
    Siena, S.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 159S - 159S
  • [40] Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients
    Cremolini, C.
    Moretto, R.
    Masi, G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1810 - 1810
12345